Download PDF
Aktuelle Neurologie 2013; 40(02): 70-78
DOI: 10.1055/s-0032-1332946
Neues in der Neurologie
© Georg Thieme Verlag KG Stuttgart · New York

Neues in der Primär- und Sekundärprävention des Schlaganfalls

New Findings in Primary and Secondary Stroke Prevention
C. Weimar
1   Universitätsklinik für Neurologie der Universität Duisburg-Essen
,
R. Weber
2   Alfried Krupp Krankenhaus Essen
,
K. Hajjar
1   Universitätsklinik für Neurologie der Universität Duisburg-Essen
,
H. C. Diener
1   Universitätsklinik für Neurologie der Universität Duisburg-Essen
› Author Affiliations
Further Information

Publication History

Publication Date:
18 February 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Anhand von selektierten Publikationen aus dem Jahr 2012 werden aktuelle Entwicklungen und Neuheiten in der Primär- und Sekundärprävention des Schlaganfalls dargestellt, die im folgenden stichwortartig zusammengefasst werden: Nierenerkrankungen sind ein unabhängiger Risikofaktor für Schlaganfall bei Patienten mit Vorhofflimmern. Auch kürzere körperliche Aktivität von 90 min pro Woche senkt das Schlaganfallrisiko. Azetylsalizylsäure (ASS) ist zur Primärprophylaxe von Schlaganfällen aufgrund der erhöhten Blutungsgefahr nicht zu empfehlen. Statine erhöhen nicht das Risiko von Hirnblutungen. Nimodipin bleibt die einzige effektive medikamentöse Behandlungsoption von Vasospasmen nach Subarachnoidalblutungen. Die Kombination von ASS und Clopidogrel führt auch bei Patienten mit kleinen subkortikalen Infarkten zu einer Erhöhung des Blutungsrisikos. Vorapaxar ist aufgrund des erhöhten intrakraniellen Blutungsrisikos nicht zur Sekundärprophylaxe nach Schlaganfall geeignet. Der transfemorale Schirmchenverschluss bei Patienten mit kryptogenem Schlaganfall und offenem Foramen ovale verhindert in einer ersten randomisierten Studie keine Schlaganfälle über einen Nachbeobachtungszeitraum von 2 Jahren. Ein extra-/intrakranieller Bypass ist sekundärprophylaktisch nicht wirksam bei Patienten mit einem symptomatischen Karotisverschluss und einem dadurch bedingten hämodynamischen Defizit. Die neuen oralen Antikoagulanzien sind auch effektiv bei Vorhofflimmerpatienten mit früherem Schlaganfall.

Abstract

Based on selected publications from 2012, current developments and innovations in primary and secondary prevention of stroke are reviewed. In patients with atrial fibrillation, renal disease is an independent risk factor for stroke. Physical activity for 90 minutes per week reduces the risk of stroke. Aspirin (acetylsalicylic acid) is not recommended for primary prevention of stroke because it increases the risk of bleeding complications. Statin therapy does not increase the risk of intracranial haemorrhage. Nimodipine remains the only effective non-invasive medical option for vasospasm in subarachnoid haemorrhage. The combination of aspirin and clopidogrel increases the risk of bleeding complications in patients with minor lacunar stroke. Vorapaxar increases the risk of intracranial bleeding and is not recommended for stroke prevention. Data from the first randomised trial indicate that endovascular closure of a patent foramen ovale (PFO) in patients with cryptogenic stroke does not prevent recurrent stroke over a follow-up of 2 years. Extra-/intracranial cerebral artery bypass operation is not effective for secondary stroke prevention in patients with haemodynamically relevant carotid artery occlusion. The novel oral anticoagulant drugs are also effective in patients with atrial fibrillation and prior stroke.

Schlüsselwörter

Schlaganfall - Hirninfarkt - TIA - Prävention

Keywords

stroke - cerebral ischemia - TIA - prevention
 

  • Literatur

  • 1 Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870
    CrossrefPubMedGoogle Scholar
  • 2 Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272
    CrossrefPubMedGoogle Scholar
  • 3 Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100
    CrossrefPubMedGoogle Scholar
  • 4 Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367: 625-635
    CrossrefPubMedGoogle Scholar
  • 5 Homma S, Thompson JL, Pullicino PM et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366: 1859-1869
    CrossrefPubMedGoogle Scholar
  • 6 Seshasai SR, Wijesuriya S, Sivakumaran R et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-216
    CrossrefPubMedGoogle Scholar
  • 7 Sjostrom L, Peltonen M, Jacobson P et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65
    CrossrefPubMedGoogle Scholar
  • 8 Wen CP, Wai JP, Tsai MK et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 2012; 378: 1244-1253
    PubMedGoogle Scholar
  • 9 Hankey GJ. Nutrition and the risk of stroke. Lancet Neurol 2012; 11: 66-81
    CrossrefPubMedGoogle Scholar
  • 10 Sesso HD, Christen WG, Bubes V et al. Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012; 308: 1751-1760
    CrossrefPubMedGoogle Scholar
  • 11 Kwak SM, Myung SK, Lee YJ et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012; 172: 686-694
    CrossrefPubMedGoogle Scholar
  • 12 Kaluza J, Wolk A, Larsson SC. Red meat consumption and risk of stroke: a meta-analysis of prospective studies. Stroke 2012; 43: 2556-2560
    CrossrefPubMedGoogle Scholar
  • 13 Lawrence M, Kerr S, McVey C et al. The effectiveness of secondary prevention lifestyle interventions designed to change lifestyle behavior following stroke: summary of a systematic review. Int J Stroke 2012; 7: 243-247
    CrossrefPubMedGoogle Scholar
  • 14 Dorhout Mees SM, Algra A, Vandertop WP et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet 2012; 380: 44-49
    CrossrefPubMedGoogle Scholar
  • 15 Macdonald RL, Higashida RT, Keller E et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke 2012; 43: 1463-1469
    CrossrefPubMedGoogle Scholar
  • 16 Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337
    CrossrefPubMedGoogle Scholar
  • 17 Benavente OR, Hart RG, McClure LA et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367: 817-825
    CrossrefPubMedGoogle Scholar
  • 18 Morrow DA, Braunwald E, Bonaca MP et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413
    CrossrefPubMedGoogle Scholar
  • 19 Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057
    CrossrefPubMedGoogle Scholar
  • 20 Furlan AJ, Reisman M, Massaro J et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366: 991-999
    CrossrefPubMedGoogle Scholar
  • 21 Mono ML, Geister L, Galimanis A et al. Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events. Stroke 2011; 42: 2891-2895
    CrossrefPubMedGoogle Scholar
  • 22 Powers WJ, Clarke WR, Grubb Jr RL et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA 2011; 306: 1983-1992
    PubMedGoogle Scholar
  • 23 Ovbiagele B, Diener HC, Yusuf S et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011; 306: 2137-2144
    CrossrefPubMedGoogle Scholar
  • 24 McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012; 43: 2149-2156
    CrossrefPubMedGoogle Scholar
  • 25 Stromberg S, Gelin J, Osterberg T et al. Very urgent carotid endarterectomy confers increased procedural risk. Stroke 2012; 43: 1331-1335
    CrossrefPubMedGoogle Scholar
  • 26 Hankey GJ, Patel MR, Stevens SR et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315-322
    CrossrefPubMedGoogle Scholar
  • 27 Easton JD, Lopes RD, Bahit MC et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-511
    CrossrefPubMedGoogle Scholar
  • 28 Diener HC, Eikelboom J, Connolly SJ et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012; 11: 225-231
    CrossrefPubMedGoogle Scholar
  • 29 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402
    CrossrefPubMedGoogle Scholar
  • 30 Jean R et al. Presented at the American Heart Association congress, Los Angeles, USA: 11/2012
    PubMed